精密医療の台頭により、バイオマーカー主導の治験が劇的に増加し、生体試料の回収と管理のための新たなプロセスと技術が必要になっています。バイオマーカーと生体試料の部では、生体試料と画像/デジタルバイオマーカー管理のリーダーが集まりバイオマーカーによる治験の複雑な要件を効果的に運用するためのベストプラクティスを共有します。パートA:臨床バイオマーカーのオペレーションとイノベーションでは、バイオマーカー主導型治験を実施するためのフレームワークとポリシーを導くため、重要なポリシー、規制、プライバシー、同意、およびガバナンスに関する考慮事項を概説します。パートB:生体試料の技術とアウトソーシングでは、生体資料回収技術の最新の進歩、患者中心の運用アプローチ、ITソリューションによる高品質の生物材料、ラボへのアクセス、バイオマーカー主導型治験に必要な診断サービスを探ります。
2月6日(月)
SCOPE's 2nd Annual Masters of Clinical Research Golf Tournament* 8:00 am
Connect with your peers and colleagues at SCOPE's 2nd Annual Masters of Clinical Research Golf Tournament.
*Limited space available. Separate registration and fee required for Golf.
Conference Registration Open9:00 am
Open Workshop: Introducing ClinEco, the New B2B Clnical Trial Community and Marketplace1:00 pm
Sit down with a small cross-industry group for a 45-minute hands-on session to learn about, share feedback, and register for free for the new B2B clinical trial community and marketplace. ClinEco unites sponsors, CRO's, service providers, and sites to streamline partnering and vendor selection. We are currently onboarding leaders in clinical research to: Explore the Ecosystem. Engage Partners. Exchange Capabilities. Walk-ins welcome. Open to all SCOPE attendees.
User Group Meetings2:00 pm
Co-locate your User Group, a Workshop or even your company's Annual Meeting with SCOPE Summit. CHI will help market the event and manage logistical operations. We will co-market prospective attendees and extend your users a discount to attend the entire SCOPE conference. We are here to work with you. Use SCOPE as your gathering point! Learn more on the SCOPE Summit website.
Part 1: Biomarker Technology and Innovation
ROOM LOCATION: Gatlin A1 & A2
ADDRESSING RACIAL INEQUITIES IN CLINICAL TRIALS & PARTICIPANT ENGAGEMENT AWARDS
Lighting a “Beacon of Hope” to Address Racial Inequity in Clinical Trials, Health, and Education
Vicky DiBiaso, MPH, BScN, Global Head, Patient Informed Development & Health Value Translation, Sanofi
Launched in July 2021 as a $33.7M commitment from Novartis and the Novartis US Foundation, Beacon of Hope began as a 10-year collaboration to increase diversity among clinical trial participants and investigators; improve access to high-quality education and promising jobs; address inherent bias in the data standards, and find actionable solutions to environmental and climate issues that disproportionately affect health among communities of color. This session brings together leaders from collaborating partner companies Novartis, Sanofi, Merck, and one of the participating HBCUs to discuss how Beacon of Hope aims to improve the quality and inclusivity of clinical trials.
Rajbir Singh, MD, Executive Director of Precision Medicine and Health Equity Trials Design, Meharry Medical College
Priscilla Pemu, Doctorate, MBBS MS FACP, Associate Dean Clinical Research at Morehouse School of Medicine
Celia J. Maxwell, MD, Associate Dean for Research, Howard University College of Medicine, Medicine & Health Affairs, Howard University Hospital
SCOPE's 7th Annual Participant Engagement Awards Introduction5:40 pm
SCOPE's 7th Annual Participant Engagement Awards
Now in its 7th year, the Participant Engagement Award (PEA) recognizes innovation and change in how the industry communicates with participants in the fields of recruitment and retention in clinical trials. PEA embodies the values and personal accomplishments of Jerry Matczak, who sadly passed away soon after receiving the inaugural 2017 award. We dedicate this award to Jerry in the hopes that it will serve as a reminder of his ideals and accomplishments. SCOPE’s 2023 Participant Engagement Award program is brought to you by Cambridge Healthtech Institute (CHI)’s SCOPE and is accepting submissions at: https://www.scopesummit.com/participant-engagement-award
SCOPE's Kick-Off Happy Hour6:30 pm

Close of Day7:45 pm
2月7日(火)
Registration Open (Gatlin Foyer)7:00 am
Morning Brew & Pastries to Jumpstart Your Day (Sponsorship Opportunities Available) or Morning Coffee7:30 am
ROOM LOCATION: Gatlin A1 & A2
THE REALITY OF A TRIAL EXPERIENCE & NAVIGATING A GLOBAL CRISIS
Would I Want My Mother to Be Part of a Clinical Trial?
Virginia Nido, Global Head, Product Development Industry Collaborations, Genentech, a member of the Roche Group
For many years, our industry has been talking about becoming more patient-centric and innovative in our approach to clinical trials and all the great things we are doing to make clinical trials more convenient for participants. But have we really changed the experience for patients or are we just continuing to admire the problem? Would you really want YOUR mother to be part of one of your clinical trials? We need to get real. It should not take a pandemic to make changes to our protocols and processes and ways of working. But we still have so far to go and together we must continue to drive an uncomfortable level of change.
Navigating a Global Crisis: Pandemic, War, Hyperinflation, Supply Chain Disruptions…You Name It
Balazs Flink, Senior Director, Clinical Development Operations, Daiichi Sankyo, Inc.
Running a complex clinical trial involves a lot of moving pieces, forward planning, modeling, allocation of resources, and a neverending ability to adjust while maintaining the highest standards. It has never been easy, but many of us in the clinical research profession know how to do our part. The advent of DCTs, novel tech and data sources, and then the pandemic put us all to the test. However, we are now facing supply chain disruptions and other human/material resource challenges that make everything even more complicated. What is a clinical ops leader to do?
Help Us Set a Guinness World Record: Join Everyone for a Group Photo at 9:25 Sharp in the Keynote to Make History!9:30 am
Grand Opening Coffee & Refreshment Break in the Exhibit Hall (Sponsorship Opportunities Available) (Gatlin BCD)9:35 am

ROOM LOCATION: St. John's 26/27
POLICY & GOVERNANCE IN AN EVOLVING HEALTH TECHNOLOGY LANDSCAPE
Novel Scientific Technologies and the Future of Evidence Generation, a Policy Perspective
Amy Abernethy, MD, PhD, President, Clinical Studies Platforms at Verily; Former Principal Deputy Commissioner, FDA
Novel scientific techniques and technologies, including cell and gene therapies, mRNA, and AI/ML, offer exciting promise for improving treatment and outcomes, but require new thinking about regulatory and evidence generation frameworks. This talk will explore the policy perspective, looking at recent FDA moves and key areas for policy innovation, with a focus on data and evidence needs. It will include lessons learned on how researchers, technologists, and study sponsors can best engage with regulators to advance novel evidence generation methods and the breakthrough technologies that can improve patient care.
Human Tissue Policies: A Critical Prerequisite for Digital Transformation
Brenda Yanak, Founder, Clinical Transformation Partners
As the industry hurtles down the path of digital transformation, the bulk of discussion has been on new tools and technologies and the interesting ways that the data produced from them can be analyzed, with occasional discussion of the need to develop data governance models. The data produced comes from human tissue - and yet there has been relatively no discussion about the development of human tissue policies and governance models. This presentation will examine the critical need for equivalent focus on development of policies governing the use of human tissue and recommended components of such a policy, to ensure that organizations position themselves for success.
Data Privacy Issues in Biobanking
David J Peloquin, PhD, Partner, Health Care, Ropes & Gray
When companies share biospecimens and associated data with external entities, issues emerge of the conditions under which the materials and data were collected, and the regulatory frameworks of privacy that apply to sharing and downstream secondary uses of the associated data. This session will explore the legal and ethical issues of provenance of human biospecimens and associated demographic phenotypic data, and how that provenance informs acceptable and ethical secondary use.

David Kaye, Vice President & General Manager, BioFortis, BioFortis, a Q2 Solutions Company
Patient samples are the lifeblood of any clinical trial but many companies are risking their data by using antiquated data collection methods (e.g.: pen & paper, homemade spreadsheets) in their modern clinical trials. In our talk, "Clinical Trial & Consent Management: Too Important to Leave to Chance" we highlight how clinical trial sample and consent tracking (CTST) software can revolutionize specimen management for pharmaceutical companies.
Transition to Lunch12:40 pm
Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own12:45 pm
Coffee & Dessert Break in the Exhibit Hall (Sponsorship Opportunities Available) (Gatlin BCD)1:15 pm

POLICY & GOVERNANCE IN AN EVOLVING HEALTH TECHNOLOGY LANDSCAPE (CONT.)
Biospecimen Governance - Key Principles and Best Practices to Consider
Rose Redfield, Head of Biospecimen Operations, Daiichi-Sankyo
What is next after carefully implementing all the operational mechanisms to collect, process, annotate and store biospecimens? How to ensure biospecimens are utilized with legal and ethical and best practices? Why would a governance structure for biospecimens be needed? When would this be beneficial? Navigating global regulations and internal expectation for research projects can be made easier with a few key principles regarding governance of utilizing biospecimens.

Hope Meely, Chief Clinical Officer, Clinical Operations, Slope
Biospecimens provide essential data for drug safety and efficacy evaluations, and yet, current regulation does not contain biospecimen management guidance. As more trials rely on sample data, especially complex oncology and cell and gene trials, are sponsors opening themselves up to regulatory risk from inconsistent operational practices that lack traceability into the sample journey?

Melissa Bime, Founder & CEO, Infiuss Health, Inc.
This talk will delve into the broader considerations surrounding the procurement of human biological specimens, including the impact of demographic representation on science and research outcomes.
Additionally, the presentation will address current limitations and the factors that must be taken into account by companies and researchers when sourcing human biological specimens. Join us as we explore the complexities of human biological specimen acquisition and its implications for the future of medicine.
Data & Specimen Governance
Karina Bienfait, PhD, Executive Director and Head, Specimen Infrastructure & Informed Consent, Global Biospecimen & Imaging Management, Bristol Myers Squibb Co.
Samar Noor, Vice President, Statistical Programming, Global Biometric Sciences, Bristol Myers Squibb Co.
Explore the data governance and specimen governance frameworks Bristol Myers Squibb has put in place to support collection and delivery of high-quality biological specimens and data for clinical research. Gain insight into key processes and technologies leveraged to ensure proper infrastructure for biospecimen collections and clinical data quality.
Biobanking and Biospecimen Operation in Precision Medicine
Lokesh Agrawal, PhD, Program Director, Biorepositories & Biospecimen Research, NIH NCI
The Cancer MoonshotSM Biobank (moonshotbiobank.cancer.gov) is a National Cancer Institute (NCI)-sponsored study that aims to accelerate cancer research through the collection of longitudinal blood and tissue biospecimens from cancer patients receiving standard of care therapy. The biospecimens, generally small biopsies, and accompanying medical data are being collected from community hospitals across US from diverse set of participant and are being made available to accelerate research progress in cancer. Evidence-based, well documented, and consistent procedures are being used to collect specimens of known quality. The Biobank will provide a networked biospecimen resource which will serve the goal of the Cancer Moonshot.
ROOM LOCATION: Gatlin Foyer
INTERACTIVE BREAKOUT DISCUSSION GROUPS
Concurrent breakout discussion groups are interactive, guided discussions hosted by a facilitator or set of co-facilitators to discuss some of the key issues presented earlier in the day’s sessions. Delegates will join a table of interest and become an active part of the discussion at hand. Bring your pharma, biotech, CRO, site, hospital or patient perspective to each of the discussions below. To get the most out of this interactive session and format please come prepared to share examples from your work, vet some ideas with your peers, be a part of group interrogation and problem solving, and, most importantly, participate in active idea sharing. Please visit the Interactive Breakout Discussion Groups Page for more information.
Welcome Reception in the Exhibit Hall (Gatlin BCD)5:00 pm

Close of Day6:30 pm
SCOPE out Pointe Orlando for an entertaining night out via our Courtesy Shuttle* (Sponsorship Opportunities Available)6:30 pm
*Courtesy shuttles will be available Tuesday and Wednesday 6:30-10:30pm (last pick up), bringing you to and from The Pointe Orlando.
The Pointe Orlando is an open air-entertainment destination, featuring local and brand names restaurants, bars, nightclubs, 20-screen movie theater, comedy club and family attractions.
Shuttles will run a continuous loop 6:30-10:30pm (last pick up) between Rosen Shingle Creek, Hilton Orlando, DoubleTree Orlando at SeaWorld, and Pointe Orlando.
On-site look for our courtesy shuttle signage directing you to pick up locations within the hotels.
2月8日(水)
ROOM LOCATION: Gatlin A3 & A4
BREAKFAST PRESENTATIONS

Caroline Jackson, Executive Vice President, Patient Services, mdgroup
Mobile health has a significant impact on patient retention and experience in clinical trials. However,it’s still under-utilized as there is a perception that more complex assessments and procedures cannot be conducted effectively in the home. This case study highlights how mdgroup worked with a client to implement complex sample collections in the homes of patients suffering from a rare disease, resulting in reduced travel burden and low dropout rates.

Dennis Akkaya, Chief Commercial Officer, myTomorrows
We would like to invite you to join us for an informative event about overcoming obstacles in recruiting patients for BioPharma clinical trials. During this event, we will delve into barriers such as lack of awareness and financial considerations that can impede clinical trial recruitment success. Additionally, impactful strategies to increase clinical trial participation and recruitment success will be shared.
ROOM LOCATION: St. John's 26/27
DATA PRIVACY AND CONSENT
Consent in Genomics: Quo Vadis?
Ma'n H. Zawati, PhD, Associate Professor, Human Genetics, Experimental Medicine, McGill University
This presentation will discuss recent consent trends in the field of genomics in both the clinical and research settings. It will touch on lessons learned from the pandemic and look into the future when it comes to data sharing, interoperability, return of results and incidental findings and many more.

Edward Ramos, PhD, Principal Science Officer Care Evolution and Co-Founder of Digital Trials Center, Scripps Research
The decentralized, digital clinical trial (DCT) model has brought a significant shift in how we conduct research. By meeting participants where they are and providing access for anyone, anywhere, digital clinical trials offer a study design that can provide real-world context as well as multi-modal data collection through survey responses, wearables, electronic health records, and other digital health technologies. Compared to traditional clinical trials, a number of innovations can be brought to the participant experience through a digital-based DCT, however, data privacy remains a priority. We will discuss the data sharing touchpoints we have with participants, how we implement strategies to support data privacy, and the return of information back to participants towards empowering them through their own, personal health insights.

Stephanie Weber, Vice President, SampleGISTICS, SampleGISTICS, LabConnect
The challenges of real-time and accurate data submission from sites requires site-centric technologies and services that all sites can easily adapt to. Topics include, obtaining day of collection data, leveraging, and integrating courier tracking, and tracking beyond the Central Lab. You will discover the options and tools available for tracking at every stage of a sample’s life cycle and the impact this knowledge has on clinical trial management and patient care.
Coffee Break in the Exhibit Hall (Sponsorship Opportunities Available)10:45 am

BIOMARKER SERVICES IN CLINICAL TRIALS FOR NOVEL THERAPEUTICS
Challenges with Patient Sampling in Cell Therapy Studies
Rebecca Blanchard, PhD, President, Blanchard Consulting
The Development path for cell therapies has distinct features as compared to historical therapies. Early drug development is often focused on characterizing the Clinical Pharmacology of a drug therapy. In the world of cell therapies, many of these traditional investigations are quite unique. For example, pharmacokinetics do not typically follow a first order enzymatic model. Measuring therapeutic cells circulating in a patient requires methods to identify cells that have been engineered. This talk will address the challenges with adequate and flexible sampling to support the development of cell therapies.
Innovative Biomarker Strategies to Advance Allogeneic CAR T Cell Development
Mark Benton, PhD, Executive Director and Head of Clinical Pharmacology, CRISPR Therapeutics
CAR T cell therapies are one of the most exciting classes on immune therapies to reach the clinic in the last 20 years. Successfully developing a CAR T cell product requires a thoughtful clinical biomarker strategy that meets the needs of scientists, physicians, and regulators as they work to understand questions surrounding dose, safety, and efficacy. This presentation will share the factors that influenced our translational pharmacology approach for developing CRISPR-engineered allogeneic CAR T cells. I will discuss ways to improve speed, flexibility, and efficiency in the setting of dose escalation studies.
Transition to Lunch12:45 pm
Part 2: Biospecimen Operations and Vendor Partnerships
Bridging Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own12:50 pm
Coffee & Dessert Break in the Exhibit Hall with "Best of Show Award" Winner Announcement (Gatlin BCD)1:20 pm

ROOM LOCATION: Gatlin A1 & A2
NEXT-GENERATION DATA SOURCES & BUILDING A ROADMAP FOR AN R&D ORGANIZATION
Faster, Better, Cheaper: The Increasing Role and Opportunities for Real-World Evidence in Informing Regulatory Pathways
Christopher Boone, PhD, Global Head, Health Economics & Outcomes Research, AbbVie, Inc.
An open dialogue on the facilitators, barriers, and open opportunities to effectively utilize RWE for informing regulatory pathways from a biopharma company perspective. Additionally, we will highlight some of the novel use cases and key lessons learned by biopharma companies in utilizing RWE for discovery and development purposes.
Advancing Evidence Generation of the Future
Amy Abernethy, MD, PhD, President, Clinical Studies Platforms at Verily; Former Principal Deputy Commissioner, FDA
Clinical research is undergoing a major shift, as we move towards continuous evidence generation to support accelerated drug development and approvals. In this talk, Dr. Abernethy will share her firsthand experience with the evolving use of real-world data and evidence at FDA during COVID. She'll speak to the need for quality longitudinal data sets, the role of technology, and how new approaches are transforming the clinical research field.
Fireside Chat: Future-Ready Operations: Building a Multi-Year Roadmap
Lynne M. Cesario, Executive Director, Global Lead Risk Based Monitoring Program, Pfizer Global R&D Groton Labs
With increases in complexity and new trial modalities, organizations need to constantly assess what the future needs. This chat will focus on the strategic choices and approaches to be considered, and how to plan out such a multi-year roadmap.
Booth Crawl & Refreshment Break in the Exhibit Hall (Sponsorship Opportunities Available). Last Chance for Viewing. (Gatlin BCD)3:25 pm

ROOM LOCATION: St. John's 26/27
DIGITIZATION AND INNOVATION IN BIOMARKER-DRIVEN TRIALS
Patient-Centric Blood Collection Technologies That Will Minimize the Impact on the Subject/Patient and Align with the Changing Healthcare Consumer
Michael Tanen, Director, Head of Laboratory Operations and Logistics, Merck
Patient-centric blood sampling, or the self-collection of samples remotely from clinical sites, has been increasingly adopted. This approach not only reduces patient burden and allows for more diverse participation in clinical trials but increases the efficiency and breadth of the trials themselves. Technology drives this shift, but the voice of the healthcare consumer has evolved and demanded this shift to remote participation, digital health devices, and convenient participation options.
Microsampling in Clinical Trials: Considerations for Patient Centricity, Operational Implementation and Biomarker Utility
Dmitri Mikhailov, PhD, Director & Global Head, Biomarker Coordination, Novartis Institutes for BioMedical Research, Inc.
The emergence of minimally invasive and patient friendly microsampling technologies can facilitate subject recruitment, improve retention, minimize blood volume and promote simplification of trial design and conduct. This talk will review utility of some of these technologies for clinical biomarkers and will cover the following key themes: Main drivers for biomarker patient centricity; key operational considerations for microsampling; and data interpretation and biomarker utility.

Hutan Ashrafian, BSc, MBA, MBBS, PhD., CMO, YourBio Health and CSO, Preemptive Health and Medicine Initiative, Flagship Pioneering, YourBio Health
With challenges across patient access, affordability, and accuracy, novel approaches to enabling siteless, decentralized, or hybrid trials where blood collection is essential are available today. Learn how YourBio Health blood collection technologies can help drive patient completion rates and lower clinical trial costs using a virtually painless method.
Best Practices in a Changing Landscape: Considering Patient Centricity, DCTs, and Digitization in your Strategy
Michael Tanen, Director, Head of Laboratory Operations and Logistics, Merck
Join this panel to explore the latest advancements in biospecimen collection technologies, patient-centric operational approaches, and IT solutions. And to discuss outsourcing and vendor management strategies to enable delivery of high-quality biological specimens, laboratory access, and diagnostics services necessary for biomarker-driven clinical trials.
Close of Day6:30 pm
SCOPE out Pointe Orlando for an entertaining night out via our Courtesy Shuttle* (Sponsorship Opportunities Available)6:30 pm
*Courtesy shuttles will be available Tuesday and Wednesday 6:30-10:30pm (last pick up), bringing you to and from The Pointe Orlando.
The Pointe Orlando is an open air-entertainment destination, featuring local and brand names restaurants, bars, nightclubs, 20-screen movie theater, comedy club and family attractions.
Shuttles will run a continuous loop 6:30-10:30pm (last pick up) between Rosen Shingle Creek, Hilton Orlando, DoubleTree Orlando at SeaWorld, and Pointe Orlando.
On-site look for our courtesy shuttle signage directing you to pick up locations within the hotels.
2月9日(木)
Registration Open (Gatlin Foyer)7:15 am
ROOM LOCATION: Gatlin A1 & A2
BREAKFAST PRESENTATIONS

Lisa Moneymaker, Chief Technology & Product Officer, Saama
Our industry is challenged to find the right resources to drive operational best practice. There is also an expectation to move at the “speed of Covid” for every trial. It feels like an either/or.
However, you can have both. You can accelerate timelines with fewer resources.
Join this exciting session to learn about:
-
The biggest time and resource drains on clinical trials
-
Applying AI/ML to improve efficiency
-
Challenging your own internal processes to get to market faster
Session Break8:15 am
ROOM LOCATION: Gatlin A1 & A2
ADVANCING CLINICAL INNOVATION AND PATIENT CENTRICITY THROUGH TECHNOLOGY AND PARTNERING
Is There Technology Overload? Finding the Right Balance for Patients and Sites
Michelle Shogren, CEO & Owner, Innovate in What You Do!
With the proliferation of digital health technologies, how can we determine the right mix to improve clinical research without overloading patients and/or sites? How do we lessen the technology adoption burden on sites? What's the future of finding patients? Facebook? Databases? Scanning EMRs? Physician engagement?
Patient-Centric Sampling at Merck: How the Patient Voice Shaped Our Sampling Strategy
Over the past decade, Merck has conducted numerous trials involving patient-centric sampling, an enabling technology for decentralized trials. Patient preference questionnaires were included in multiple trials. Questionnaires revealed that at-home sampling methods with novel collection devices are preferred and preference is dependent upon sampling frequency, sampling methods, pain tolerance, and physiological condition. Data indicate that effective patient-centric sampling approaches should be painless, simple for users to execute, and minimize sample volume. This participant feedback has shaped our company’s patient-centric sampling strategy and has enabled us to implement sampling approaches that are truly patient-centric.

Alison Holland, Executive General Manager, Digital and Decentralized Solutions, Medable
The industry is heading towards a place where digital elements (DCT’s) start to become standard as we operate trials. To achieve scale, and give patients a true choice, digital strategies need to be embedded early into drug development and embraced by sites, patients and sponsors. Join us as we discuss the path to the new normal for everyone in the clinical trials ecosystem.

The clinical trial industry has been experimenting with Virtual Waiting Rooms (VWRs) in support of patient recruitment and enrollment, but today the use cases vary dramatically and the tools are still in the nascent stages of development. This session examines VWRs across several companies, the challenges VWRs address and current recommendations from early applications.

Dawn Anderson, Managing Director, Life Sciences, Deloitte
The industry is looking to new site network models focused on community-based clinics. By being embedded in the community, new site networks may be able to increase patient recruitment & convenience, improve retention, & enhance diversity in clinical trials. We will discuss strategies and ways non-traditional site networks could transform the clinical trial delivery model.
Networking Coffee Break (Gatlin Foyer)10:45 am
ROOM LOCATION: Gatlin A4
SCALING DCT EFFORTS BEYOND ZIP CODE AND COMPANY LIMITS
Real-World Results from Ongoing DCT Collaboration
DCT design requires more complexity than brick-and-mortar research. Despite your best intentions, items can get overlooked. Our real-world experience can help guide you to success by demonstrating what we overlooked or dismissed and what we learned.
Cross Industry Initiatives to Ease DCT Adoption: Updates from DTRA
Craig Lipset, Founder & Advisor, Clinical Innovation Partners; Co-Chair, Decentralized Trials & Research Alliance (DTRA)
The Decentralized Trials & Research Alliance enables collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
Jane E. Myles, Co-Lead, Priority Iniative 3B, DCT Playbook, Decentralized Trials & Research Alliance (DTRA)
Transition to Lunch12:40 pm
SCOPE Send Off Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own12:45 pm
Closing Remarks1:15 pm
Scope Summit 2023 Adjourns1:20 pm
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。